Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurizio Callari

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Nature Communications|March 4, 2025
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapiesMaurizio Callari, Matteo Dugo, Marco Barreca, et al.
The Journal of Pathology|October 25, 2024
A comprehensive luminal breast cancer patient-derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4/6 inhibitorsIlenia Segatto, Maria Chiara Mattevi, Gian Luca Rampioni Vinciguerra, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2023
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment responseCarlo Bosi, Áron Bartha, Barbara Galbardi, et al.
BMC Genomics|April 22, 2009
A transcriptional sketch of a primary human breast cancer by 454 deep sequencingAlessandro Guffanti, Michele Iacono, Paride Pelucchi, et al.
Critical Reviews in Oncology/Hematology|May 8, 2024
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathwaysBrenno Pastò, Giulia Buzzatti, Clorinda Schettino, et al.
NPJ Precision Oncology|June 15, 2026
Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapyGiulia Notini, Barbara Galbardi, Giulia Viale, et al.
Molecular Oncology|April 15, 2025
A large-scale retrospective study in metastatic breast cancer patients using circulating tumour DNA and machine learning to predict treatment outcome and progression-free survivalEmma J Beddowes, Mario Ortega Duran, Solon Karapanagiotis, et al.
International Journal of Molecular Sciences|May 28, 2022
Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH StudyLaura Mannarino, Lara Paracchini, Federica Pezzuto, et al.
Nature Communications|April 1, 2021
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug responseDimitra Georgopoulou, Maurizio Callari, Oscar M Rueda, et al.
Nature|March 15, 2019
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroupsOscar M Rueda, Stephen-John Sammut, Jose A Seoane, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Nature Communications|March 4, 2025
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapiesMaurizio Callari, Matteo Dugo, Marco Barreca, et al.
The Journal of Pathology|October 25, 2024
A comprehensive luminal breast cancer patient-derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4/6 inhibitorsIlenia Segatto, Maria Chiara Mattevi, Gian Luca Rampioni Vinciguerra, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2023
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment responseCarlo Bosi, Áron Bartha, Barbara Galbardi, et al.
BMC Genomics|April 22, 2009
A transcriptional sketch of a primary human breast cancer by 454 deep sequencingAlessandro Guffanti, Michele Iacono, Paride Pelucchi, et al.
Critical Reviews in Oncology/Hematology|May 8, 2024
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathwaysBrenno Pastò, Giulia Buzzatti, Clorinda Schettino, et al.
NPJ Precision Oncology|June 15, 2026
Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapyGiulia Notini, Barbara Galbardi, Giulia Viale, et al.
Molecular Oncology|April 15, 2025
A large-scale retrospective study in metastatic breast cancer patients using circulating tumour DNA and machine learning to predict treatment outcome and progression-free survivalEmma J Beddowes, Mario Ortega Duran, Solon Karapanagiotis, et al.
International Journal of Molecular Sciences|May 28, 2022
Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH StudyLaura Mannarino, Lara Paracchini, Federica Pezzuto, et al.
Nature Communications|April 1, 2021
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug responseDimitra Georgopoulou, Maurizio Callari, Oscar M Rueda, et al.
Nature|March 15, 2019
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroupsOscar M Rueda, Stephen-John Sammut, Jose A Seoane, et al.
Pageof 7